Key facts
- Drug class: incretin mimetics — glucagon-like peptide-1 receptor agonists, plus newer dual and triple receptor agonists.
- Approval status: exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide and orforglipron are FDA approved. Retatrutide is investigational.
- Route: mostly subcutaneous injection, daily or weekly. Two oral options exist: oral semaglutide and orforglipron.
- Licensed uses: type 2 diabetes, chronic weight management, and for some agents cardiovascular risk reduction and obstructive sleep apnea.
- Evidence level: the strongest in the peptide world — dozens of phase 3 randomized trials and cardiovascular outcome trials with tens of thousands of participants.
- Most reported side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite.
- Legal status: prescription-only medicines. Grey-market vials labelled for research use are not part of the approved supply chain.
What are GLP-1 agonists?
A GLP-1 agonist is any drug that binds and activates the receptor for glucagon-like peptide-1. GLP-1 itself is a 30-amino-acid hormone secreted by L-cells in the small intestine and colon within minutes of a meal. It is one of the two main incretin hormones, the signals your gut sends to your pancreas and brain to say that food has arrived.
Native GLP-1 is useless as a drug. The enzyme dipeptidyl peptidase-4 cleaves it almost immediately, giving the natural hormone a circulating half-life of only one to two minutes (PubMed 17928588). The entire drug class exists because chemists found ways around that problem: swapping the amino acid DPP-4 attacks, attaching fatty acid chains that bind albumin, or fusing the peptide to an antibody fragment. Each modification stretched the half-life from minutes to hours to days, which is why the class went from twice-daily injections in 2005 to once-weekly pens today (PubMed 31050435).
The first agent, exenatide, was not a redesigned human peptide at all. It is a synthetic version of exendin-4, a peptide from Gila monster venom that activates the human GLP-1 receptor and resists DPP-4. Everything since has been an exercise in making that action last longer, hit harder, or reach more than one receptor.
How do GLP-1 receptor agonists work?
GLP-1 receptors are not confined to the pancreas. They appear in the stomach, heart, kidney, vagal nerves and several brain regions, which is why one hormone produces such a wide set of effects.
Four mechanisms do most of the work. First, glucose-dependent insulin secretion: the drugs amplify insulin release from pancreatic beta cells only when blood glucose is elevated, which is why the class carries a low intrinsic risk of hypoglycemia on its own. Second, glucagon suppression, reducing the liver's output of glucose after meals. Third, delayed gastric emptying, so food leaves the stomach more slowly and glucose enters the bloodstream more gradually. Fourth, and most relevant to body weight, central appetite suppression — activation of receptors in appetite-regulating brain circuits reduces hunger and food reward signalling (PubMed 34067710).
People on these drugs describe it as food noise going quiet. That subjective change is the mechanism by which the weight loss happens: participants in the trials ate less because they wanted less, not because they were instructed to restrict harder than the placebo group.
The same delayed gastric emptying that helps glucose control is also the source of most of the side effects. Nausea, fullness, reflux and constipation are the direct downstream consequence of a stomach that empties more slowly. It is the same lever pulled in two directions.
Every drug in the class, from exenatide to retatrutide
The class has evolved in three waves. The first wave were straightforward GLP-1 mimetics. The second wave added a second incretin receptor. The third wave, still in trials, adds a third hormone target.
Exenatide (Byetta, Bydureon) reached the US market in 2005, first twice daily and later as an extended-release weekly formulation. Liraglutide (Victoza for diabetes, Saxenda for weight) followed as the first once-daily human GLP-1 analogue, using a fatty acid chain to bind albumin. Dulaglutide (Trulicity) fused GLP-1 to an antibody fragment for weekly dosing. Lixisenatide was a shorter-acting exendin derivative. Head-to-head trials across this generation consistently ranked the longer-acting agents ahead of the shorter-acting ones for both glucose control and weight (PubMed 33767808).
Semaglutide changed the ceiling. Marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily tablet, it delivered weight reductions that had previously required surgery. Tirzepatide (Mounjaro and Zepbound) went further by activating the GIP receptor as well as GLP-1 — a dual agonist rather than a pure GLP-1 drug. Retatrutide adds glucagon receptor agonism on top of both, making it a triple agonist, and remains investigational.
Read the individual profiles for semaglutide, tirzepatide, liraglutide and retatrutide, or the broader overview of peptides studied for weight loss.
Do GLP-1 agonists actually work for weight loss?
Yes, and the effect size is unusually large for a metabolic drug. The comparison below uses the primary weight endpoint from each drug's pivotal randomized trial. These are trial-administered doses reported for context, not recommendations.
| Drug | Receptors targeted | Form | Pivotal trial weight result | Status |
|---|---|---|---|---|
| Exenatide | GLP-1 | Injection, twice daily or weekly | Modest; EXSCEL was a cardiovascular safety trial, not a weight trial | FDA approved (diabetes) |
| Liraglutide | GLP-1 | Injection, daily | −8.0% vs −2.6% placebo at 56 weeks (SCALE, 3.0 mg) | FDA approved |
| Dulaglutide | GLP-1 | Injection, weekly | Small; REWIND was a cardiovascular outcome trial | FDA approved (diabetes) |
| Semaglutide | GLP-1 | Injection weekly; also a daily tablet | −14.9% vs −2.4% placebo at 68 weeks (STEP 1, 2.4 mg) | FDA approved |
| Tirzepatide | GIP + GLP-1 | Injection, weekly | −20.9% vs −3.1% placebo at 72 weeks (SURMOUNT-1, highest dose) | FDA approved |
| Orforglipron | GLP-1 (small molecule) | Oral tablet, daily | Up to −12.4% at 72 weeks (ATTAIN phase 3 program) | FDA approved April 2026 |
| Retatrutide | GIP + GLP-1 + glucagon | Injection, weekly | −24.2% at 48 weeks (phase 2, highest dose) | Investigational |
In STEP 1, 1,961 adults with obesity and without diabetes received weekly semaglutide 2.4 mg or placebo for 68 weeks. Mean body weight fell 14.9% on drug versus 2.4% on placebo, and 86% of the semaglutide group lost at least 5% of body weight (PubMed 33567185). In SURMOUNT-1, 2,539 adults received weekly tirzepatide at 5, 10 or 15 mg for 72 weeks; the highest dose group lost 20.9% versus 3.1% on placebo (PubMed 35658024). The direct head-to-head, SURMOUNT-5, gave tirzepatide a 20.2% reduction against 13.7% for semaglutide over 72 weeks (PubMed 40353578).
Two caveats matter. Weight loss is consistently smaller in people who also have type 2 diabetes — SURMOUNT-2 reported a 14.7% reduction at the highest tirzepatide dose in that population (PubMed 37385275). And every one of these trials paired the drug with a reduced-calorie diet and increased activity in both arms. The drug is the differential, not the whole intervention. See tirzepatide vs semaglutide for the full head-to-head breakdown.
What do they do for blood sugar and heart risk?
Glucose lowering was the original indication and remains the best-characterized effect. Across the class, HbA1c reductions of roughly 1 to 2 percentage points are typical, achieved with a low rate of hypoglycemia when the drug is used without insulin or sulfonylureas, because the insulin-releasing effect is glucose-dependent.
The cardiovascular outcome trials are what moved this class from useful to important. LEADER randomized 9,340 people with type 2 diabetes to liraglutide or placebo; major adverse cardiovascular events occurred in 13.0% versus 14.9%, a statistically significant reduction (PubMed 27295427). REWIND found a similar benefit for dulaglutide across 9,901 participants (PubMed 31189511). Not every agent delivered: EXSCEL found weekly exenatide noninferior to placebo for safety but not superior for efficacy, with events in 11.4% versus 12.2% (PubMed 28910237). The class benefit is not uniform.
The landmark result came from SELECT, which enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes. Weekly semaglutide 2.4 mg cut major adverse cardiovascular events by 20% relative to placebo (PubMed 37952131). That trial established cardiovascular benefit as a reason to treat obesity pharmacologically, independent of glucose.
GLP-1 agonist side effects reported in trials
Gastrointestinal adverse events dominate the safety profile of every drug in the class. Across the phase 3 programs the most frequently reported are nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, eructation and reduced appetite. In STEP 1, nausea and diarrhea were reported by roughly 40% and 30% of the semaglutide group respectively, mostly transient and mostly during dose escalation. Discontinuation due to gastrointestinal events occurred in about 4.5% of that group versus 0.8% on placebo (PubMed 33567185).
Rarer but more serious events have been studied separately. A population-based cohort analysis published in JAMA compared people using GLP-1 agonists for weight loss against users of bupropion-naltrexone and reported increased hazard ratios for pancreatitis, bowel obstruction and gastroparesis, with no significant increase in biliary disease (PubMed 37796527). The absolute event rates were low, but the relative signal was consistent enough to matter clinically. Gallbladder disease has also been reported more often with rapid weight loss on liraglutide (PubMed 28392927).
Injection-site reactions, a heart rate increase of a few beats per minute, and transient rises in pancreatic enzymes also appear across trials. Diabetic retinopathy complications have been flagged in some semaglutide datasets.
Class warnings and who they are not for
Every approved GLP-1 and dual agonist in the United States carries a boxed warning about thyroid C-cell tumors, based on rodent studies in which the drugs caused medullary thyroid carcinoma. Whether that translates to humans is unresolved, but the labels contraindicate use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Other label cautions include a history of pancreatitis, severe gastrointestinal disease including gastroparesis, pregnancy and breastfeeding, and — because of delayed gastric emptying — the timing of anesthesia, which has prompted specific perioperative guidance from anesthesiology societies. People on insulin or sulfonylureas face a real hypoglycemia risk from the combination even though the GLP-1 drug alone rarely causes it. None of this is something to work out from an article; it is a conversation with a prescriber.
What happens when you stop a GLP-1 agonist?
The effect is not durable after withdrawal. In the randomized withdrawal extension of the STEP 1 program, participants who stopped semaglutide regained roughly two-thirds of the weight they had lost within one year, and the improvements in waist circumference, blood pressure, lipids and HbA1c moved back toward baseline alongside it (PubMed 35441470).
That finding reframed the class. These are not courses of treatment with an endpoint; the trial evidence supports them as ongoing therapy for a chronic condition, the way blood pressure medication is. Cost and long-term tolerability become part of the clinical picture rather than footnotes.
Are GLP-1 agonists FDA approved and legal?
Most of the class is approved and legal with a prescription. Exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, tirzepatide and orforglipron all hold FDA approvals across type 2 diabetes and chronic weight management indications, with additional approvals for cardiovascular risk reduction and obstructive sleep apnea attached to specific agents. In the UK, EU, Canada and Australia they are similarly prescription-only.
Retatrutide is not approved anywhere. Neither are the many peptide vials sold online under research-chemical labelling, which sit entirely outside the regulated manufacturing and pharmacovigilance system that produced the safety data on this page. Purity, sterility and actual peptide content are unverified in that channel. Our guide to the legal status of peptides covers the distinction in more depth.
The next generation: dual, triple and oral agents
Three directions define what comes next. More receptors. Retatrutide's phase 2 obesity trial reported a mean 24.2% weight reduction at 48 weeks at the highest dose, the largest figure published for any pharmacological agent to date, with a companion trial in type 2 diabetes and a further study in metabolic dysfunction-associated steatotic liver disease (PubMed 37366315, PubMed 37385280, PubMed 38858523). Phase 3 results will decide whether that holds.
Different hormones entirely. Cagrilintide is an amylin analogue, not an incretin. Combined with semaglutide it produced greater weight loss than either component alone in a large 68-week randomized trial (PubMed 40544433) — see our cagrilintide profile.
Oral delivery. Peptides are destroyed by stomach acid and gut proteases, which is why almost all of them are injected (PubMed 15984901). Oral semaglutide solved this with an absorption enhancer and strict fasting conditions. Orforglipron, approved in April 2026, sidesteps the problem completely by not being a peptide at all — it is a small molecule that activates the same receptor and can be taken at any time of day without food or water restrictions.
Frequently asked questions
Are GLP-1 agonists the same thing as Ozempic?
No. Ozempic is one brand of one drug in the class. GLP-1 agonist is the category name for every medicine that activates the GLP-1 receptor, including exenatide, liraglutide, dulaglutide, semaglutide and the newer oral agent orforglipron. Ozempic is the semaglutide brand licensed for type 2 diabetes; Wegovy is the same molecule licensed at a higher strength for weight management.
Do GLP-1 agonists work if you do not have diabetes?
Yes, for weight. The STEP 1 and SURMOUNT-1 trials enrolled adults with obesity but without type 2 diabetes and reported average weight reductions of 14.9 percent and up to 20.9 percent respectively, versus roughly 2 to 3 percent on placebo. The SELECT trial also found a 20 percent reduction in major cardiovascular events in people with obesity and heart disease but no diabetes.
How long does it take for a GLP-1 agonist to work?
Appetite suppression is often noticeable within the first weeks, and blood glucose responds early. Weight loss accumulates far more slowly. In the pivotal 68 to 72 week trials the weight curves were still declining near the end of the study, meaning most participants had not reached a plateau after more than a year of treatment. These are long-horizon medicines, not quick fixes.
Which GLP-1 agonist causes the most weight loss?
Among approved drugs, tirzepatide has produced the largest average reductions. In SURMOUNT-5, a head-to-head trial, tirzepatide reduced body weight by 20.2 percent versus 13.7 percent for semaglutide over 72 weeks. The investigational triple agonist retatrutide reached 24.2 percent at 48 weeks in phase 2, but it is not approved and phase 3 results are still pending.
What are the most common GLP-1 side effects?
Gastrointestinal effects dominate every trial in the class: nausea, vomiting, diarrhea, constipation, abdominal pain, burping and reduced appetite. They are usually worst during dose escalation and ease over time, but they are the leading reason participants stop treatment. Less common but more serious reported events include pancreatitis, gallbladder disease, bowel obstruction and gastroparesis.
Do you regain weight after stopping a GLP-1 agonist?
Usually, yes. In a randomized withdrawal analysis of the STEP 1 extension, participants who stopped semaglutide regained about two thirds of the weight they had lost within one year, and improvements in blood pressure and lipids drifted back toward baseline. Obesity behaves like a chronic condition in these datasets, and stopping the drug removes the effect.
Are GLP-1 agonists FDA approved and legal?
Several are FDA approved and legal with a prescription, including exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide and orforglipron. They are prescription-only drugs in the United States, the United Kingdom, the EU and most other jurisdictions. Retatrutide remains investigational. Vials sold online as research chemicals fall outside that approved supply chain and are not quality assured.
Can you take a GLP-1 agonist as a pill instead of an injection?
Yes, two oral options exist. Oral semaglutide is a peptide tablet that needs an absorption enhancer and strict fasting conditions, because peptides are otherwise destroyed in the gut. Orforglipron, approved in April 2026, is a small molecule rather than a peptide, so it can be swallowed at any time of day without food or water restrictions.
Is tirzepatide a GLP-1 agonist?
Tirzepatide activates the GLP-1 receptor, so it belongs to the broader class, but it is more precisely a dual agonist. It also activates the GIP receptor, a second incretin pathway. That extra target is the leading explanation for the larger weight reductions seen in the SURMOUNT program and in the head-to-head SURMOUNT-5 comparison against semaglutide.
Do GLP-1 agonists cause muscle loss?
Some of the weight lost on any substantial calorie deficit is lean mass, and body composition substudies in the GLP-1 trials show the same pattern. The proportion reported is broadly comparable to what is seen with diet-induced weight loss of similar magnitude. This is an active research area and is one reason combination agents that preserve lean mass are being studied.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- The physiology of glucagon-like peptide 1 — PubMed 17928588
- Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMed 31050435
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
- The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE) — PubMed 26132939
- Liraglutide for weight management: a critical review of the evidence — PubMed 28392927
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — PubMed 33567185
- Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — PubMed 35658024
- Tirzepatide once weekly for obesity in people with type 2 diabetes (SURMOUNT-2) — PubMed 37385275
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — PubMed 40353578
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) — PubMed 27295427
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) — PubMed 31189511
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL) — PubMed 28910237
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — PubMed 37952131
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss — PubMed 37796527
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — PubMed 37366315
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes — PubMed 37385280
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease — PubMed 38858523
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — PubMed 40544433
- Oral delivery of peptide drugs: barriers and developments — PubMed 15984901